BASF's Specialty-Chemicals Bet Takes Shape as Evonik Talks Hang in the Balance
Published on 10/11/2026 at 16:21 | Editorial boerse-global.de
A fatal accident at BASF's flagship Ludwigshafen site and an unresolved takeover question surrounding Evonik are testing the chemical giant on two very different fronts — one operational, one strategic — even as it rolls out products aimed squarely at the data-center boom.
A workplace death in Ludwigshafen
On Thursday, a worker employed by an outside contractor was killed at the South section of BASF's main Ludwigshafen complex while carrying out excavation work with an excavator. The company has launched an investigation to establish exactly how the accident unfolded, and police and public prosecutors are also looking into the circumstances. The incident serves as a reminder of the operational risks embedded in the group's tightly integrated production sites.
New products aimed at AI infrastructure
Even as that investigation gets under way, BASF is pushing ahead on the commercial front. On Thursday it introduced GLYTHERMIN DC PG 25, a coolant designed for data centers and certified for use in NVIDIA's DSX system — a direct play on the surging demand for heat management in high-performance server installations. The company's thermoplastic portfolio is also being positioned for higher operating temperatures and the fast data-transfer requirements of modern electronics, with the new Ultrason grades targeting the electronics industry, where components must withstand extreme thermal loads.
The push extends to industry events as well. At the SEPAWA Congress 2026, BASF experts are scheduled to deliver several presentations on October 14.
Evonik: an offer rejected, a foundation undecided
Behind these product launches lies a far larger strategic question. BASF has confirmed exploratory talks with Essen-based rival Evonik, which turned down an initial offer of EUR 22.15 per share as inadequate, according to Reuters sources. CEO Markus Kamieth has argued that combining with another strong specialty-chemicals player makes sense above all on industrial grounds, the Handelsblatt reported.
Should investors sell immediately? Or is it worth buying BASF?
The RAG-Stiftung, Evonik's major shareholder, has so far declined to commit to a valuation, with its board taking the view that the two companies should first make their positions clear. Direct negotiations between the parties have not been taking place recently, Reuters sources said — a situation that could pave the way for protracted and costly haggling.
That leaves investors weighing two competing paths: organic growth in higher-margin niches, or large-scale M&A. The deciding factor, in either case, is capital discipline. Expanding specialty chemicals such as coolants and high-performance plastics demands sustained spending on research and market roll-out — segments that offer attractive margins but require patience before meaningful market share materializes. A sweetened bid for Evonik, by contrast, would bring substantial integration costs, while an overly hesitant approach risks leaving scale advantages on the table.
Buyback support and the chart picture
Management has been supporting the share price in the meantime. Under its ongoing buyback program, BASF repurchased 805,398 of its own shares a little over a week ago.
The stock closed Friday's session at EUR 51.63. Despite recent volatility, it is up 16 percent since the start of the year, and sits 6.2 percent below its 52-week high of EUR 55.05. On the technical side, the 200-day moving average of EUR 49.83 marks the line in the sand: as long as the shares hold above it, the uptrend remains intact, but a sustained break below that support would open the door to a sharper correction.
What could tip the scales
In an optimistic scenario, BASF establishes its new specialties quickly in the market. Broad adoption of GLYTHERMIN among data-center operators would let the company ride the global build-out of computing capacity, while additional earnings power from the new Ultrason grades would strengthen group profitability from within. Success on that front would reduce the need for risky large-scale acquisitions, and if management can demonstrate a rising return on invested capital, the market is likely to reward it with a higher valuation — giving the stock the momentum to challenge the EUR 55.05 52-week high over the medium term.
The downside case is shaped by the risk of financial strain and site-related incidents. Should BASF decide to raise its offer for Evonik substantially, integration costs could mount. If earnings from the new specialty chemicals fall short of expectations while acquisition spending stays high, margins would come under pressure, and rising debt could unsettle investors further.
Concrete markers will define the next move. Beyond the technical picture, market watchers are focused on any fresh developments in the exploratory talks. Clarity on the operating health of BASF's segments arrives at the end of the month, when the company publishes its quarterly financial report for the third quarter of 2026 on October 28.
Ad
BASF Stock: New Analysis - 11 October
Fresh BASF information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
